Summary of Recent Advances and Unmet Needs for Patients With eBC

Author(s):

Kevin Kalinsky, MD, MS,Virginia Kaklamani, MD

Panelists discuss key updates from the past year regarding HR+/HER2– early breast cancer (eBC), emerging research that could transform treatment approaches, and the role of new biomarkers in patient identification, stratification, and predicting CDK4/6 inhibitor responses; they also highlight studies on the horizon that may further refine treatment strategies and offer closing clinical pearls for diagnosing and managing early-stage breast cancer.

EP: 1.Introduction and HR+/HER2– eBC Overview

EP: 2.Approaches to eBC Diagnosis and Risk Stratification

EP: 3.CDK4/6 Inhibitors Treatment Options in the eBC Setting

EP: 4.Clinical Trial Considerations for eBC Treatment Selection

EP: 5.Clinical Decision-Making for a Patient With eBC: Scenario and Strategies

EP: 6.Managing CDK4/6 Inhibitor Toxicities and Encouraging Adherence

EP: 7.Multidisciplinary Treatment Sequencing and Coordination

Now Viewing

EP: 8.Summary of Recent Advances and Unmet Needs for Patients With eBC

Video content above is prompted by the following:

Can you please summarize key learnings and updates that have emerged this past year around HR+/HER2– eBC?
What emerging research is on the horizon that could change management of HR+/HER2– eBC?
1. Are there any emerging biomarkers that could aid in patient identification and stratification as well as predict CDK4/6 inhibitor treatment response?
2. Which studies are on the horizon with potential to improve the treatment landscape?
What are some closing thoughts and clinical pearls you would highlight regarding diagnosis and management of early-stage breast cancer?